Test Price
2,000 AED✅ Home Collection Available
ONCOPRO KRAS Rapid Test in UAE – 2,000 AED – Next-Day Results
Executive Summary & Core Metrics
Core Metrics & UAE Trust Signals
The ONCOPRO KRAS Rapid Test is a molecular diagnostic assay using real-time PCR (qPCR) to detect actionable KRAS gene mutations (codons 12, 13, 61, and 146) in formalin-fixed paraffin-embedded (FFPE) tumor tissue. This test provides 99.9% analytical sensitivity and reports results within the next working day when samples are received by 11 AM. It is performed under ISO 9001:2015 accreditation (Cert: INT/EGQ/2509DA/3139) at our DHA-licensed laboratory (License No. 1143) in Dubai Healthcare City. The results guide critical oncology decisions regarding anti-EGFR therapy eligibility for colorectal, lung, and pancreatic cancers.
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- ✓ Premium Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval – temperature-controlled transport for FFPE blocks. No home phlebotomy required for this archival tissue test.
- ✓ Clinical Guidance: Post-test telephonic result interpretation by DHA-licensed oncology liaison team.
- ✓ Insurance: Direct billing verification via WhatsApp +971 54 548 8731. Accepted by major UAE insurers.
Test Overview & Methodology
The ONCOPRO KRAS Rapid Test detects clinically relevant KRAS mutations using real-time PCR (qPCR), a gold-standard method offering closed-tube, contamination-free analysis with analytical sensitivity down to 1% variant allele frequency. Results are critical for determining eligibility for anti-EGFR monoclonal antibody therapy (cetuximab, panitumumab) in patients with metastatic colorectal cancer, non-small cell lung cancer, and pancreatic ductal adenocarcinoma. Wild-type KRAS (no mutation) indicates potential benefit from anti-EGFR therapy; mutant KRAS directs clinicians toward alternative targeted agents such as VEGF inhibitors or chemotherapy combinations.
| Parameter | ONCOPRO KRAS Rapid Test | Alternative: NGS Panel / Sanger Sequencing |
|---|---|---|
| Precision (Analytical Sensitivity) | 99.9% – Detects mutant alleles at ≤1% VAF | 95–98% – VAF detection limit typically 5–10% |
| Methodology | Real-Time PCR (qPCR) – gold standard, closed-tube | Sanger Sequencing or Broad NGS – longer, higher cost |
| Turnaround Time | Next working day (sample received by 11 AM) | 7–14 days |
| Tissue Requirement | FFPE block with ≥10% tumor tissue | FFPE block or 10–15 unstained slides; often ≥20% tumor |
| Cost (UAE) | 2,000 AED | 3,500–8,000 AED |
Physician Insight & Safety Protocols
Mr. Prabhakar Reddy Kalathoor — Specialist Diagnostic Radiology, DHA ID: 61713011 — "The KRAS mutation status is a pivotal decision node in modern oncology. A KRAS-mutant tumor renders anti-EGFR therapy ineffective and potentially harmful, while a wild-type result opens the door to targeted biologic agents that dramatically improve outcomes in metastatic colorectal cancer. I advise every patient to interpret these results alongside their treating oncologist, as the test guides future therapeutic strategy and does not warrant immediate changes to ongoing treatment."
Important Clinical Advisory
Do not discontinue, modify, or adjust any prescribed medication – including chemotherapy, targeted therapy, or supportive care – based solely on this test result. KRAS mutation status informs future treatment strategy and must be interpreted in context of full clinical history. Any changes to therapy should only be made under direct supervision of your treating physician.
Safety Exclusion Criteria & Emergency Red Flags
Specimen Rejection Criteria
- FFPE block with less than 10% tumor tissue content.
- Improperly fixed tissue (fixation delayed beyond 6 hours or duration <6 hours).
- Decalcified tissue specimens (acid-based decalcification degrades DNA).
- Block without corresponding H&E-stained slide for pathological review.
- Unlabeled or mismatched specimen container.
Patient Emergency Red Flags
- New-onset severe abdominal pain, obstruction symptoms, or inability to pass stool.
- Acute shortness of breath, chest pain, or hemoptysis in known lung cancer.
- Jaundice, intractable vomiting, or signs of biliary obstruction.
- Fever ≥38.5°C with neutropenia (if on active chemotherapy).
- Any acute neurological change, seizure, or focal weakness.
If you experience any of the above, proceed to the nearest Emergency Department immediately. This test result does not replace urgent clinical evaluation.
Patient FAQ & Clinical Guidance
1. What is the ONCOPRO KRAS Rapid Test and why has my oncologist ordered it?
The ONCOPRO KRAS Rapid Test detects specific mutations in the KRAS gene from your tumor tissue to guide targeted cancer therapy decisions. KRAS mutations are found in approximately 40% of colorectal cancers, 30% of non-small cell lung cancers, and over 90% of pancreatic cancers. Mutant KRAS renders anti-EGFR therapies (cetuximab, panitumumab) ineffective. Your oncologist orders this test to ensure you receive only treatments proven effective against your specific tumor biology.
2. How must the FFPE tissue block be prepared and submitted?
Submit a formalin-fixed paraffin-embedded tissue block containing at least 10% tumor tissue, shipped at room temperature with a corresponding H&E slide for pathology review. Our laboratory accepts samples daily until 11 AM; results are reported the next working day. The FFPE block should be placed in a sealed biohazard specimen bag with the completed requisition form. Our medical liaison team can coordinate retrieval of archived blocks from external hospitals – contact +971 54 548 8731.
3. How long does it take to get results and what does a positive result mean?
Results are available within one working day with 99.9% accuracy. A positive result indicates the presence of a KRAS mutation that makes anti-EGFR therapy ineffective. Your oncologist will then recommend alternative treatments such as standard chemotherapy, VEGF inhibitors (e.g., bevacizumab), or other targeted agents. A negative result (wild-type KRAS) means the tumor may respond to anti-EGFR therapy, opening effective treatment options. Always discuss results with your treating oncologist for full clinical context.
UAE Regulatory & Data Privacy Adherence
Your Data and Rights Are Protected
- Data Protection: All patient data is handled in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Your test results are encrypted, access-controlled, and never shared without explicit consent.
- Medical Liability & Consent: Informed consent for genetic analysis is obtained in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability. You have the right to refuse testing or withdraw consent at any time.
- Accreditation: Our laboratory holds ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and operates under DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | ONCOPRO KRAS Rapid Test |
| Price (AED) | 2,000 AED |
| Turnaround Time | Next working day (sample received by 11 AM) |
| Sample Type / Matrix | Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Block (≥10% tumor tissue) |
| Methodology Used | Real-Time PCR (qPCR) |
| ICD-10-CM Code | C18.9 (Malignant neoplasm of colon, unspecified), Z15.09 (Genetic susceptibility to other malignant neoplasm), C25.9 (Malignant neoplasm of pancreas, unspecified) |
| LOINC Code | 21702-3 (KRAS gene mutation analysis in Tissue by Molecular genetics method) |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians